Abstract
The title compound, [Cu2(C14H10Cl2NO2)4(C2H6OS)2], comprises a CuII 2 core that is quadruply bridged by four carboxylate ligands with the dimethyl sulfoxide ligands binding along the Cu⋯Cu axis. The four carboxylate ligands bind in a bidentate syn–syn bridging mode. Molecules reside on crystallographic inversion centres bisecting the mid-point of the Cu⋯Cu axis. There are no intermolecular interactions of note.
Highlights
The title compound, [Cu2(C14H10Cl2NO2)4(C2H6OS)2], comprises a Cu2II core that is quadruply bridged by four carboxylate ligands with the dimethyl sulfoxide ligands binding along the Cu Cu axis
CuII complexes of non-steroidal anti-inflammatory drugs (NSAIDs) show enhanced anti-inflammatory activity and reduced gastrointestinal toxicity compared with their uncomplexed parent drug, see: Weder et al (2002)
The structure of the Cu–NSAID is likely to be an important factor for its biological activity
Summary
Reims Champagne Ardenne, Moulin de la Housse, BP 1039, 51687 Reims cedex 2, France. R factor = 0.031; wR factor = 0.079; data-to-parameter ratio = 27.3. The title compound, [Cu2(C14H10Cl2NO2)4(C2H6OS)2], comprises a Cu2II core that is quadruply bridged by four carboxylate ligands with the dimethyl sulfoxide ligands binding along the Cu Cu axis. The four carboxylate ligands bind in a bidentate syn–syn bridging mode. Molecules reside on crystallographic inversion centres bisecting the mid-point of the Cu Cu axis. There are no intermolecular interactions of note
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
